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Malignant melanoma is oneof the mostaggressive malignancies in human and is responsiblefor almost60% of lethal skin tumors.
Its incidence has been increasing in white population in the past two decades. There is a complex interaction of environmental
(exogenous) and endogenous, including genetic, risk factors in developing malignant melanoma. 8–12% of familial melanomas
occur in a familial setting related to mutation of the CDKN2A gene that encodes p16. The aim of this is to brieﬂy review the
microanatomy and physiology of the melanocytes, epidemiology, risk factors, clinical presentation, historical classiﬁcation and
histopathology and, more in details, the most recent discoveries in biology and genetics of malignant melanoma. At the end, the
ﬁnal version of 2009 AJCC malignant melanoma staging and classiﬁcation is presented.
1.Introduction
The epidermis contains two types of dendritic cells, besides
keratinocytes, thatcouldmimic eachother: Langerhans’cells
and melanocytes. Langerhans’ cells are dendritic antigen
processing cells and hence play a primary role in cellu-
lar response to tumor antigens, skin graft rejection, and
microorganism [1, 2]. Langerhans’ cells are located in the
suprabasal layer of the epidermis, a feature diﬀerentiating
them from melanocytes on routine H&E stain. Melanocytes
originatefromtheneuralcrestandincontrasttoLangerhans’
cellsarelocatedamongstthebasallayeroftheepidermis,hair
bulb, eyes, ears, and meninges [3–5]. Melanocyte migration
to the epidermis, function, and its survival are all dependant
on expression of the tyrosine kinase receptor c-kit gene
[4, 6]. The pigmentary system of the skin is a complex
set of reactions with many potential sites for dysfunc-
tion [7]. Melanin pigment is produced by melanocytes in
their speciﬁc cytoplasmic organelles called melanosomes.
Melanosomes may represent a variant of lysosome [8], in
which tyrosinase acts on the substrate tyrosine, resulting in
dopa and dopaquinone formation [9, 10]. Melanin pigment
synthesized by each melanocyte is transferred to an average
of 36 keratinocytes. PAR-2 on the keratinocyte surface is a
keyreceptorinthistransfer[11,12].Thetransferredmelanin
then forms a cap at the top of nucleus of mitotically active
basal cells and prevents the ultraviolet injurious eﬀects on
nucleus. Melanin stains with Masson-Fontana silver method,
based on a positive argentaﬃn reaction, in which means the
melanocytes take up silver and then reduce it to a visible
metallic state, without the aid of a reducing agent.
2. Epidemiology
Theincidenceofmalignantmelanomahasbeenincreasingin
white populations [13–15]. Although malignant melanoma
comprises less than 5% of malignant skin tumors; however,
it is responsible for almost 60% of lethal skin neoplasia [16].
OneofthehighestincidenceratesisinQueensland,Australia
[17]. The incidence of malignant melanoma appears to be
lower and stable in darkskin individuals (Africans, Native
Americans, Asians, and Hispanics). Decreased incidence
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an inﬂux of low risk immigrants [18–21]. With increased
life expectancy of the elderly population, melanoma will
be a public health challenge [22]. Increased incidence of
melanoma is partly due to early detection (thin melanomas)
and partly due to true increase of incidence. Despite the
increase in the incidence of melanoma, the prognosis has
been improving due to earlier diagnosis of thin melanomas
and hence in a curable stage [23–25]. The incidence of
melanoma is equal in men and women and uncommon in
children although there are reports that the incidence may
be higher in women. A typical patient is usually a Caucasian
adult in the 4th decade of life with lesion on the back and leg
in male and female, respectively. One typical study revealed
that the most common sites in decreasing order are the trunk
(43.5%), extremities (33.9%), acral sites (11.9%), and head
and neck (10.7%) [16].
3. Risk Factors
Thereisacomplexinteractionofenvironmental(exogenous)
andendogenousfactors.Upto65%ofmalignantmelanomas
are sun-related [26–28] .T h er o l eo fc h r o n i cs u ne x p o s u r ei s
controversial. Some studies suggested that total accumulated
exposure to sunis a very important factorwhereaslong-term
occupational exposure actually may be protective [29, 30].
In either case the general acceptance is that intermittent sun
exposure is the most important factor. The list of risk factors
in developing malignant melanoma is long and includes pale
skin, blond or red hair, numerous freckles and tendency to
burn and tan poorly (predominantly skin phototype 1–3)
[26–28, 31], presence of more than 50 acquired (common,
banal) nevi [32], more than ﬁve dysplastic (atypical, Clark’s)
nevi, large congenital nevi [33, 34], nevi larger than 6mm
[35], PUVA therapy, tendency to sunburn and tan poorly,
use of tanning salons, Xeroderma pigmentosum, immuno-
suppression, chemical exposures, scars, Marjolin’s ulcer [36–
39], and genetic factors. In fact 8%–12% of malignant
melanomas occur in a familial setting which may be related
to mutations of the CDKN2A gene that encodes p16 and is
linked to chromosome 9p21 [40, 41].
4. ClinicalPresentation
Typical malignant melanomas usually present as “Malignant
Melanoma ABCD”: asymmetry, border irregularity, color
variegation, diameter more than 6mm. However, many
exceptions may occur as they may do in other medical
disciplines.
5.Diagnosis
Any suspicious pigmented lesions must be biopsied to rule
out or rule in melanoma. Even though dermascopy, even
in the hands of a relatively inexpert practitioner, may show
highdiagnosticaccuracy[42]andboosttheclinicalsuspicion
in diagnosing malignant melanoma; however, the deﬁnitive
diagnosis is conﬁrmed done by biopsy.
6.Classiﬁcationand Histopathology
Historically, malignant melanoma was classiﬁed by Wallace
Clark and coworkers into superﬁcial spreading type, lentigo
malignant type, and nodular type [43, 44]. Later on Dr.
Richard Reed added a fourth type called acral lentiginous
malignant melanoma [45]. Since then the classiﬁcation
of malignant melanoma with their relative incidences has
been as follows: superﬁcial spreading melanoma (50%–
75%), nodular melanoma (15%–35%), lentigo maligna
melanoma (5%–15%), acral lentiginous melanoma (5%–
10%), desmoplastic melanoma (uncommon), miscellaneous
group (Rare).
Melanoma presents three clinically and histomorpholog-
ically discernable steps in tumor progression [46].
(1) Malignant Melanoma conﬁned to the epidermis
(melanoma in situ), which is called Radial Growth
Phase- (RPG-) conﬁned melanoma.
(2) Radial Growth Phase (RGP)-conﬁned microinvasive,
which shows some malignant cells present in superﬁ-
cial papillary dermis.
(3) Vertical Growth Phase (VGP), which means
melanoma, has entered the tumorigenic and/or
m i t o g e n i cp h a s e( u s u a l l yC l a r k ’ sl e v e lI Ia n d
occasionally Clark’s level III).
The importance of RPG is best demonstrated by the
Taran and Heenan study, which showed development of
metastatic melanoma in only 5 of 1716 patients with level
2 melanomas (= 1mm thick) in 7 to 14 years followup
[47]. Those 5 cases with metastatic melanomas revealed
regression.
6.1. Superﬁcial Spreading Melanoma (SSM). SSM is the most
common melanoma that can occur at any site and at any
age [48]. About 75% of SSMs occur de novo. The classic
lesions show variation in pigmentation and pagetoid spread
of melanoma cell in epidermis.
6.2. Nodular Melanoma (NM). NM melanoma by deﬁnition
has no radial growth phase and could be nodular, polypoid,
or pedunculated [49, 50].
6.3. Lentigo Maligna Melanoma (LMM). This variant occurs
on the sun-exposed skin, face, and upper extremities of
elderly patients [51]. Lentigo maligna (also called Hutchin-
sonfreckle)isbasicallyinsitumelanomaandischaracterized
by epidermal atrophy, extensive solar, lentiginous, and back-
to-back proliferation of melanoma cells with nest formation
with extension into cutaneous adnexa. Only 5% of patients
with lentigo maligna progress to lentigo maligna melanoma,
and it usually takes several years [52]. Several methods
of therapy can be used to treat lentigo maligna including
cryotherapy, superﬁcial radiation, and surgical excision with
mapping and modiﬁed Mohs’ surgery [53–55].
6.4. Acral Lentiginous Melanoma (ALM). ALM is common
on palmar, plantar, and ungual skin of Black and JapaneseDermatology Research and Practice 3
people [56]. Ulcerate and melanonychia striata may occur.
Although this type of melanoma is common in the above-
mentioned locations, other types of malignant melanoma
may still develop at the same location [57]. Most of the
mucosal melanomas including oral cavity, vulva vagina,
and cervix uteri follow the histological features of acral
lentiginous melanomas [58, 59].
7.RareVariants
There are rare variants of malignant melanoma that do
not show the typical classical histopathology. Amongst
these variants, Desmoplastic Melanoma (DM)/Neurotropic
Melanoma is worth mentioning more in detail since it could
easily be misdiagnosed as ﬁbroblastic proliferation and scar.
This variant usually presents as indurated plaque or bulky
t u m o ro nt h eh e a da n dn e c kl o c a t i o n[ 60] and is char-
acterized by paucicellular proliferation of atypical dermal
spindle melanocytes, dermal collections of lymphocytes with
overlying epidermis commonly showing lentigo maligna
[61]. This variant also commonly shows neurotropism. The
dermal component of desmoplastic melanoma is usually
negative for Melan A (or Mart1) and HMB45. These two
immunostains, however, highlight the presence of Lentigo
maligna in situ. Both the epidermal component and dermal
atypical spindle melanocytes are positive for S100 immunos-
tain. Other rare variants include nevoid melanoma [62,
63], verrucous melanoma, small cell melanoma, signet ring
melanoma, myxoid melanoma, osteogenic melanoma of the
ﬁnger, animal (Equine/pigment synthesizing) melanoma,
childhood melanoma excongenital nevus, and minimal
deviation malignant melanoma. Minimal deviation subtype
is characterized by uniform proliferation of melanocytes that
show minimal cytomorphological atypia [64].
8. Prognostic Factors in Melanoma
There are three classes of adverse prognostic factors in
melanoma: pathological, clinical, and other factors including
genetic alteration. The ﬁrst group includes increasing the
Breslow thickness [65], ulceration, mitotic rate, Clark level
[44], absent or nonbrisk tumor inﬁltrating lymphocytes
[66], regression [67, 68], microscopic satellites [69], lym-
phovascular invasion [70], angiotropism, tumor volume,
neurotropism, cell type, local recurrence, histopathologic
subtype, and presence of vertical growth phase. Clinical
adverse factors include increasing age, male, location of the
lesion, and metastasis.
9.TheBiology andGeneticsof
MalignantMelanoma
Two genes have been discovered in melanoma families:
CDKN2A (p16) on chromosome 9p21 and CDK4 on
chromosome 12 [70, 71] .T h eC D K N 2 Ag e n ea c t sa sat u m o r
suppressor gene and plays a crucial role in cell cycle regula-
tion and senescence. Mutations of the CDKN2A gene confer
susceptibility to familial melanoma. Partial or complete
loss of p16 expression has also been identiﬁed in sporadic
melanomas. Other genes, such as MC1R (Melanocortin 1
Receptor) and DNA repair genes, are likely to be more
important in determining susceptibility for melanoma in the
general population [72].
Although nevi and melanomas share initiating genetic
alterations such as oncogenic mutations in BRAF and NRAS,
melanomas often show recurrent patterns of chromosomal
aberrations such as losses of chromosomes 6q, 8p, 9p, and
10q along with gains of chromosomes 1q, 6p, 7, 8q, 17q,
and 20q, while benign nevi tend to have no detectable chro-
mosomal aberrations by comparative genomic hybridization
(CGH) or karyotyping [73–75]. Recently, a ﬂuorescence in
situ hybridization- (FISH-) based test, using a combination
of 4 FISH probes targeting 3 loci on chromosome 6 (RREB1
and MYB genes) and 1 on chromosome 11 (Cyclin D1
gene), was developed [76, 77]. The method is applicable to
formalin-ﬁxed paraﬃn-embedded tissue and has the most
powerfuldiscriminatoryabilitybetweenmelanomaandnevi.
Metastatic melanoma is an incurable disease with high
mortality rate. Patients with metastatic disease have an
average survival of <1 year. This high mortality rate is largely
theresultoftheresistancetochemotherapyandradiotherapy
[78, 79]. Transformation of melanocytes to melanoma cells
is still largely unclear [78]. A combination of up- or down-
regulation of various eﬀectors acting on diﬀerent molecular
pathways appears to be involved in progression of normal
melanocyte to metastatic malignant cells [80]. Numerous
studies using tissue specimens, cell lines, and xenografts
to discover the mechanism(s) behind this transformation,
invasiveness, and metastasis are in progress.
Alteration of cell cycle proteins (e.g., cyclin D1, pRb,
and p16) has a role in transformation and progression in
melanocytic tumors. It has been shown that progressive loss
of p16 can be seen in transformation of benign nevi to
melanoma and to metastatic melanoma. Progressive increase
in expression of cyclin D1 and pRb is associated with
progression to melanoma cells; however, cyclin D1 and pRb
show relative decrease in thick melanoma and metastatic
melanoma [81].
HigherexpressionofPAR-1(protease-activatedreceptor-
1) is seen in melanoma cell lines and tissue specimens.
Upregulation of PAR-1 mediates high levels of Cx-43 (gap
junctional intracellular communication molecule connexin)
expression. This molecule is involved in tumor cell dia-
pedesis and attachment to endothelial cells [82]. Type
I collagenase and PAR-1 activating functions of MMP-1
(matrix metalloproteinase-1) are required for melanoma
progression. Highly expressed MMP-1 is suggested to be
involved in progression of noninvasive melanoma to invasive
vertical growth phase by degrading type I collagen of skin
[83].
Protein Kinase C (PKC) mediates signals for cell growth
and is a target of tumor-promoting phorbol esters in
malignant transformation [84].
Downregulation of E-cadherin and upregulation of N-
cadherin may be seen in melanoma cells. Such shift of cad-
herin proﬁle may have a role in uncontrolled proliferation,
invasion, and migration [85].4 Dermatology Research and Practice
S100A1, S100B, Bcl-2, and CD44 have been described in
transformation of melanocytes to melanoma cells. S100A1
expression is increased in contrast to S100B, which shows
higher expression in benign nevi. The Sviatoha et al.
demonstrated studies of a higher expression of CD44 antigen
in melanomas with known metastases than in those without
metastases, but this diﬀerence was not statistically signiﬁcant
[86].InteractionofthetranscriptionfactorE2F-1withRGFR
can act as driving force in melanoma progression [87].
The studies of Mehnert et al., based on the fact that
angiogenesis is one of the factors required for progres-
sion and melanoma metastasis, demonstrated that vascular
endothelial growth factor (VEGF) and its receptors (VEGF-
R1, VEGF-R2, and VEGF-R3) are higher in melanomas and
advanced melanomas than in benign nevi. VEGF-R2 shows
higherexpressionofVEGF-R2inmetastaticmelanomasthan
in primary melanoma [88].
Using immunochemistry on human tissue, it has been
shown that there is signiﬁcantly higher cortactin (a mul-
tidomain actin-binding protein important for the function
of cytoskeleton) expression in melanomas than in nevi
and higher expression in metastatic melanoma than in
invasive primary melanomas [89]. MHC (major histocom-
patibility complex) molecule overexpression in earlier stages
of melanoma and downregulation in metastatic malignant
melanoma have been observed [90].
PEDF (pigment epithelium-derived factor) loss appears
to be associated with invasive phenotype and malignant
progression [91]. Deregulation of microRNAs (miRNAs)
using cell lines from primary or metastatic melanoma
contributes in formation and progression of melanoma [92].
Melanoma chondroitin sulfate proteoglycan (MCSP) facili-
tates the growth, motility, and invasiveness of tumor cells.
MCSP expression is associated with increased expression of
c-Met and HGF. c-Met inhibition limits growth and motility
of melanoma cell lines [93]. Up-regulated expression of C-
Raf is seen in a subset of melanomas [94].
ATP-binding cassette (ABC) transporters regulate the
transport of physiologic substrates. ABC-transporter mRNA
expression proﬁle may have some roles in melanoma
tumorigenesis [95]. It has been suggested that there is
transient upregulation of cDNA clone pCMa1 in neoplastic
progression of melanocytes [96].
It has been shown that angiogenesis and metastasis
can be inhibited by heparin and its derivatives. The study
conducted by Kenessey et al. revealed that fragments of
heparin, not involved in its haemostatic eﬀect, may have a
role in antimigratory and antimetastatic processes [97].
10. Treatment of Malignant
Melanoma andFollowup
Avoiding sunlight if possible, frequent use of sunscreen
and routine checkups in high risk patients are important
preventive measures. Sometimes the use of sunscreen is
associated with higher incidence of malignant melanoma
but in fact this is in due to modiﬁed sun-exposure behavior
[98, 99]. Adequate clear resection margins handling of the
reexcision specimens and sentinel lymph node biopsies are
important factors in management of malignant melanoma.
A variety of protocols for excision of primary cutaneous
melanomas exist. One commonly used protocol [100–104]
is in situ melanoma: 0.5cm clear margin, <1mm: 1cm
clear margin 1–2mm 1–2cm clear margin (depending on
the location), 2–4mm 2cm clear margin, >4mm3cmclear
margin.Thesentinellymphnodeistheﬁrstnodeinthebasin
of the regional lymph node that picks up the
99mTc and/or
blue dye. Sentinel node biopsy has had a signiﬁcant impact
on managing patients of melanoma [105].
Surgical excision, interferon therapy, hypothermic iso-
latedlimbperfusionwithmelphalan,CO2laserablation,and
intralesional BCG have been used for treatment of in-transit
melanoma. In-transit melanoma metastasis is deﬁned by
in-transit cutaneous malignant melanoma deposits between
the site of excision and the draining lymph nodes [106]
more than 2cm from primary melanoma, which is diﬀerent
from satellite metastasis deﬁned by lesions less than 2cm
from the primary melanoma. Despite of diﬀerent deﬁnitions
the biologic behaviour of both is similar and is categorized
as intralymphatic metastasis as another criterion in the
N category regardless of the number of lesions based on
the ﬁnal version of the 2009 AJCC melanoma staging and
classiﬁcation [107, 108]. Patients with positive nodes or
node-negative melanomas thicker than 4mm, ulceration,
or Clark’s level IV or V may beneﬁt of adjuvant therapy.
Interferon-alpha 2b is the most commonly used FDA-
approved adjuvant therapy [109]. There is no deﬁnite proof
that longevity of patients is aﬀected by routine laboratory
tests such as lactate dehydrogenase (LDH) and/or imaging
studies such as CT scan, MRI, and PET scan. There
are several guidelines, which recommend limited use of
laboratory test and imaging based on the disease stage. Low
yield, high rate of false-positive tests, and lack of signiﬁcant
impact of early detection of metastases on survival argue that
chestX-rayandserumLDHshouldprobablynotbeaccepted
into routine clinical practice in clinically localized melanoma
in the absence of data supporting their use [110, 111].
However, patients with higher stage may beneﬁt from these
tests.
11. Final Version of 2009 AJCC Melanoma
Stagingand Classiﬁcation
In the ﬁnal version of 2009 AJCC, the 7th edition [107],
the mitotic rate permm2 has been added to staging of
melanoma. Mitosis = 1p e r m m 2 is included in primary
criterionfordeﬁningT1bmelanoma.Immunohistochemical
detection of nodal metastasis has also been incorporated
and must include at least one melanoma-associated marker
(e.g., HMB45, Melan-A, and Mart-1) unless diagnostic
cellular morphology is present. In addition there is no lower
threshold of staging N disease [107]. The new Melanoma
Staging Database clearly demonstrates that an elevated
LDH is an independent and highly signiﬁcant predictor
of survival or outcome of stage IV malignant melanoma.
LDH is amongst the most predictive independent factorsDermatology Research and Practice 5
of diminished survival when is analyzed in a multivariate
analysis [107, 112, 113].
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